ArticleNature medicine2026

Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial.

Choong-Kun Lee et al.PubMed ↗Publisher ↗

No numbers read from the abstract.